Original title: “Cancer”

global prevalence of peripheral neuropathy following chemotherapy in cancer patients a systematic review and meta analysis

Original title: “The global prevalence of peripheral neuropathy following chemotherapy in cancer patients: a systematic review and meta-analysis.”

Eikon Therapeutics’ IPO haul will support a lead program that could expand the scope of cancer immunotherapy. Eikon’s stock market debut builds on growing IPO momentum, following upsized offerings from Aktis Oncology and Veradermics. This program is in clinical testing in two common types of cancer and Eikon has raised $381 million in IPO cash to support this drug and others in its pipeline. Late Wednesday, Eikon priced its offering of 21.2 million shares at $18 apiece, up from the 17.6 million shares the company initially planned to offer in the range of $16 to $18 each. Those shares began trading on the Nasdaq Thursday under the stock symbol “EIKN.” Eikon’s stock market debut builds on growing biotech IPO momentum. Aktis Oncology had the first biotech IPO of the year in January. Veradermics began trading as a public company Wednesday. Eikon was founded in 2019 and emerged from stealth in 2021, revealing $148 million in funding and former Merck executive Roger Perlmutter as its CEO. Prior to the IPO, Eikon had raised more than $1.1 billion; its most recent financing was a $350.7 million Series D round nearly a year ago. “We also believe that the design of EIK1001 to activate innate and adaptive immune anti-tumor responses creates the potential to explore additional indications, including both highly immunogenic tumors, which have been shown to be susceptible to immunotherapy, and moderately and low immunogenic tumors, where current immune therapies have demonstrated little to no activity,” the company said in the IPO filing. ... In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases

Original title: “Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials - MedCity News”

Despite the Phase 1 cull, CEO Vas Narasimhan on Wednesday maintained that Novartis continues to invest in its early-stage pipeline, looking for deals in the “sub-$2-billion range.”

Original title: “Novartis Cuts 6 Early Cancer Candidates, Adds 2 to Refine Oncology Strategy”

Data-driven, patient-first: using insights in striving to transform cancer care

Original title: “Patient-centric oncology trials”

The Orphan Drug Act revolutionized rare disease treatment, yet rising costs and access issues challenge equitable health care solutions. Policy debates now center on whether the Orphan Drug Act’s incentives remain aligned with unmet need, leaving patients, their caregivers, and their care teams to navigate a patchwork of prior authorization requirements, benefit exclusions, and inconsistent definitions of medical necessity. Diagnostic innovations, such as the ability to now identify BRCA-positive cancers, permit more distinct disease classifications, making oncology fertile ground for orphan drug designations with improved mortality trends and marking a sharp contrast to the decades before the Orphan Drug Act’s passage in which effective cancer treatments were limited, especially for pediatric patients. The ORPHAN Cures Act provision of the new bill included 2 significant changes regarding this: Drugs can have more than 1 indication for a rare disease or condition, and a rare drug will only become eligible for price negotiation starting with the date of the first nonorphan indication. Drilling down to Medicare Part B and Part D for patients with blood cancers, Waters noted, the updated provision under the ORPHAN Cures Act means that drugs for these patients that may have become eligible for negotiation no longer would be. More than 40 years after its passage, the Orphan Drug Act has fundamentally reshaped the rare disease landscape—fueling scientific innovation, expanding therapeutic pipelines, and transforming once-neglected conditions into active areas of research and development. But its success has also exposed fault lines: rising prices, uneven access, and policy frameworks that struggle to accommodate small, heterogeneous patient populations.

Original title: “Is Rare Disease Policy a Stress Test of US Health Care? | AJMC”

Washington, DC, Feb. 03, 2026 (GLOBE NEWSWIRE) -- National Association of Specialty Pharmacy (NASP) President and CEO Sheila Arquette, R.Ph. and Chairman... Specialty pharmacies serve communities of patients who have complex health conditions like cancer, rheumatoid arthritis, multiple sclerosis, cystic fibrosis, hemophilia, organ transplantation and rare diseases. Specialty pharmacies are accredited by an independent, third party nationally recognized accreditation organization ensuring consistent quality of extensive drug management and clinical patient care services. NASP has long advocated for this law, which we believe will stabilize and strengthen the specialty pharmacy infrastructure that complex therapies depend on—supporting innovation, adherence, and improved long-term outcomes for patients with cancer, autoimmune diseases, rare disorders, and other serious conditions,” said Scott Guisinger. For too long, specialty pharmacies have faced underwater reimbursement, opaque practices, and restrictive networks that have forced many qualified providers out of network and disrupted continuity of care for some of the sickest patients in America. This landmark federal action represents the most significant step yet toward ending those practices,” said Sheila Arquette. 22, 2026 (GLOBE NEWSWIRE) -- The National Association of Specialty Pharmacy (NASP) applauds the House for taking decided action today to enact reforms to support Medicare... Read More · January 21, 2026 15:31 ET | Source: National Association of Specialty Pharmacy (NASP) Pharmacist and Pharmacy Organizations Including NASP Commend 2026 Spending Bill with Important PBM Provisions, Urge Passage · Washington, DC, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The National Community Pharmacists Association, the National Association of Chain Drug Stores, FMI – The Food Industry Association, the National...

Original title: “NASP Applauds Congressional Passage of Landmark Bill to Protect Patient Access to Specialty Pharmacies and Support Specialty Pharmacy Businesses”

DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified pyrrolobenzodiazepine payload.

Original title: “Daiichi Sankyo Dumps Next-Gen ADC From Development Pipeline”

In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide an opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Original title: “Proposed Collection; 60-Day Comment Request; NCI Genomic Data Commons (GDC) Data Submission Request Form (National Cancer Institute)”

CDC conducts and supports studies to reduce cancer and eliminate health disparities.

Original title: “Cancer Research”

The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Evaluating the Impact of Training and Technical Assistance (TTA) Programs for NCCCP

Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”

Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized initial public offering, signaling strong investor demand for 2026's first U.S. listing. Wall Street is expecting biotech IPOs to rebound in 2026 after sweeping changes at the U.S. health regulator and funding cuts by the Trump administration hindered listings from the sector last year. Lilly's move builds on its partnership with Aktis, struck in 2024, to develop tumor-targeting radiopharmaceuticals. "Eli Lilly’s commitment ... shows that (Aktis') cancer-targeting technology has passed the scrutiny of a major industry leader," said IPOX research associate Lukas Muehlbauer. "This backing is particularly significant because Big Pharma has been actively buying innovation in the sector," Muehlbauer said, pointing to the acquisitions in 2023 of radiopharma startups RayzeBio and Point Biopharma shortly after their IPOs. Basil writes stories across the U.S. finance file including banks, asset managers, payment firms, insurers, and exchange operators. He also covers initial public offerings on U.S. exchanges and venture capital funding.

Original title: “Aktis Oncology secures Lilly as anchor investor for upsized US IPO | Reuters”

Referred to the House Committee on Education and Workforce.

Original title: “HR 4101: Cancer Drug Parity Act of 2025”

Transcript of teleconference

Original title: “Vital Signs: Teleconference on Obesity and Cancer - Transcript”

Overweight and obesity are associated with increased risk of 13 types of cancer. These cancers account for about 40 percent of all cancers diagnosed in the United States in 2014.

Original title: “Cancer and Obesity - Digital Press Kit”

Overweight and obesity are associated with increased risk of 13 types of cancer. These cancers account for about 40 percent of all cancers diagnosed in the United States in 2014

Original title: “Cancers Associated with Overweight and Obesity Make up 40 percent of Cancers Diagnosed in the United States - Press Release”

Overweight and obesity are associated with at least 13 different types of cancer. According to the latest CDC Vital Signs report, cancers associated with overweight and obesity accounted for 40 percent of cancers diagnosed in the U.S. in 2014. About 2 in 3 of these cancers are in adults 50- to 74-years-old.

Original title: “CDC Telebriefing: New Vital Signs Report - Why is the overall cancer rate declining, while cancer rates associated with overweight and obesity are on the rise? - Media Advisory”

Despite decreases in cancer death rates nationwide, a new report shows slower reduction in cancer death rates in rural America (a decrease of 1.0 percent per year) compared with urban America (a decrease of 1.6 percent per year),

Original title: “New CDC Report shows deaths from cancer higher in rural America - Press Release”

CDC releases NEW, interactive U.S. Cancer Statistics data displays that improve the access to and look of the official federal cancer statistics.

Original title: “U.S. Cancer Statistics Data Visualization Website”

Overall cancer death rates continue to decrease in men, women, and children for all major racial and ethnic groups, according to the latest Annual Report to the Nation on the Status of Cancer, 1975-2014.

Original title: “Annual Report to the Nation: Cancer Death Rates Continue to Decline - Press Release”